Orthogon TherapeuticsOrthogon Therapeutics
Orthogon Therapeutics

Orthogon Therapeutics

Developing first-in-class oral therapy for BK polyomavirus infections.

Website
2012Inactive3
Advertise here

About

Orthogon Therapeutics is a biotechnology startup focused on developing a first-in-class oral therapy to treat BK polyomavirus (BKV) infections. BKV infections are a significant cause of complications in transplant patients, and currently, there are no approved treatments. The company's pioneering therapy aims to address the full spectrum of BKV infection, from early reactivation to more severe manifestations.

Technology stack

detected 2026-06-10
Est. monthly stack spend~$80/mo
EmailGoogle Workspace
Hosting
Google Cloud
Comments

No comments yet. Be the first to share your take.

Frequently asked

What does Orthogon Therapeutics do?

Orthogon Therapeutics is a biotechnology startup focused on developing a first-in-class oral therapy to treat BK polyomavirus (BKV) infections. BKV infections are a significant cause of complications in transplant patients, and currently, there are no approved treatments. The company's pioneering therapy aims to address the full spectrum of BKV infection, from early reactivation to more severe manifestations.

How much funding has Orthogon Therapeutics raised?

Orthogon Therapeutics has raised a total of $35M in funding. The most recent round on record is Follow-on.

Where is Orthogon Therapeutics headquartered?

Orthogon Therapeutics is headquartered in Canton, Massachusetts, USA.

When was Orthogon Therapeutics founded?

Orthogon Therapeutics was founded in 2012.

What industry does Orthogon Therapeutics operate in?

Orthogon Therapeutics operates in Biotechnology, Pharmaceuticals, Healthcare, Biotech, Drug Discovery, Clinical Trials.

How many employees does Orthogon Therapeutics have?

Orthogon Therapeutics has approximately 3 people on record.

What is Orthogon Therapeutics's current status?

Orthogon Therapeutics's current operating status is: Inactive.